Lannett has struck a deal with Chinese respiratory specialist Respirent to gain exclusive US distribution rights to Respirent’s proposed generic version of GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol).
The deal runs for 10 years from the point at which Lannett starts distributing the generic in the US following US Food and Drug Administration approval
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?